 The acute treatment for diarrhea will be left to physicians discretion in both groups. Patients in the control arm will be treated without Octreotide LAR. Patients in the experimental arm will receive the first dose of Octreotide LAR 30 mg at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR with an interval of 28 days between them, until chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first. Patient evaluation will be done at each cycle for efficacy and toxicity. 